294 related articles for article (PubMed ID: 36104744)
21. Clinicoradiological characteristics of primary spinal cord H3 K27M-mutant diffuse midline glioma.
Cheng L; Wang L; Yao Q; Ma L; Duan W; Guan J; Zhang C; Wang K; Liu Z; Wang X; Wang Z; Wu H; Chen Z; Jian F
J Neurosurg Spine; 2022 Feb; 36(2):303-314. PubMed ID: 34560639
[TBL] [Abstract][Full Text] [Related]
22. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
[TBL] [Abstract][Full Text] [Related]
23. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
24. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract][Full Text] [Related]
25. Indolent presentation of a diffuse midline glioma, H3 K27-altered.
Damodharan S; Helgager J; Puccetti D
Childs Nerv Syst; 2023 Mar; 39(3):833-835. PubMed ID: 36094605
[TBL] [Abstract][Full Text] [Related]
26. Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma.
Hohm A; Karremann M; Gielen GH; Pietsch T; Warmuth-Metz M; Vandergrift LA; Bison B; Stock A; Hoffmann M; Pham M; Kramm CM; Nowak J
Clin Neuroradiol; 2022 Mar; 32(1):249-258. PubMed ID: 34919158
[TBL] [Abstract][Full Text] [Related]
27. Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging.
Li J; Zhang P; Qu L; Sun T; Duan Y; Wu M; Weng J; Li Z; Gong X; Liu X; Wang Y; Jia W; Su X; Yue Q; Li J; Zhang Z; Barkhof F; Huang RY; Chang K; Sair H; Ye C; Zhang L; Zhuo Z; Liu Y
J Magn Reson Imaging; 2023 Sep; 58(3):850-861. PubMed ID: 36692205
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of H3 K27M-mutant gliomas in adults.
Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
[TBL] [Abstract][Full Text] [Related]
29. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.
Schulte JD; Buerki RA; Lapointe S; Molinaro AM; Zhang Y; Villanueva-Meyer JE; Perry A; Phillips JJ; Tihan T; Bollen AW; Pekmezci M; Butowski N; Oberheim Bush NA; Taylor JW; Chang SM; Theodosopoulos P; Aghi MK; Hervey-Jumper SL; Berger MS; Solomon DA; Clarke JL
Neurooncol Adv; 2020; 2(1):vdaa142. PubMed ID: 33354667
[TBL] [Abstract][Full Text] [Related]
30. Low-Grade Gemistocytic Morphology in H3 G34R-Mutant Gliomas and Concurrent K27M Mutation: Clinicopathologic Findings.
Morris M; Driscoll M; Henson JW; Cobbs C; Jiang L; Gocke CD; Chen L; Rodriguez FJ
J Neuropathol Exp Neurol; 2020 Oct; 79(10):1038-1043. PubMed ID: 32954438
[TBL] [Abstract][Full Text] [Related]
31. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
32. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
[TBL] [Abstract][Full Text] [Related]
33. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
34. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
35. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
van den Bent M; Saratsis AM; Geurts M; Franceschi E
Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
[TBL] [Abstract][Full Text] [Related]
36. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
[TBL] [Abstract][Full Text] [Related]
37. A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor.
Funata N; Nobusawa S; Nakata S; Yamazaki T; Takabagake K; Koike T; Maegawa T; Yamada R; Shinoura N; Mine Y
Brain Tumor Pathol; 2018 Jan; 35(1):29-35. PubMed ID: 29264735
[TBL] [Abstract][Full Text] [Related]
38. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.
Kleinschmidt-DeMasters BK; Mulcahy Levy JM
Clin Neuropathol; 2018; 37 (2018)(2):53-63. PubMed ID: 29393845
[TBL] [Abstract][Full Text] [Related]
39. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.
Castel D; Kergrohen T; Tauziède-Espariat A; Mackay A; Ghermaoui S; Lechapt E; Pfister SM; Kramm CM; Boddaert N; Blauwblomme T; Puget S; Beccaria K; Jones C; Jones DTW; Varlet P; Grill J; Debily MA
Acta Neuropathol; 2020 Jun; 139(6):1109-1113. PubMed ID: 32193787
[No Abstract] [Full Text] [Related]
40. H3 K27M mutation in rosette-forming glioneuronal tumors: a potential diagnostic pitfall.
Marastoni E; Ammendola S; Rossi S; Giovannoni I; Broggi G; Masotto B; Feletti A; Barresi V
Virchows Arch; 2024 Jan; ():. PubMed ID: 38233563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
